Event-Driven Stocks

Mirum Pharmaceuticals, Inc.

MIRMNasdaq

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 3 good● 2 warning● 2 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$521.3M$336.9M$186.4M$77.1M$19.1M$0
Operating income−$22.1M−$87.6M−$109.2M−$131.2M−$173.4M−$104.3M
Net income−$23.4M−$87.9M−$163.4M−$135.7M−$84.0M−$103.3M
Total assets$842.8M$670.8M$646.6M$352.9M$294.7M$240.9M
Total liabilities$528.1M$445.1M$398.0M$210.9M$174.4M$68.8M
Equity$314.7M$225.6M$248.7M$142.0M$120.2M$172.1M
EPS (diluted)$-0.47$-1.85$-4.00$-4.02$-2.77—
Shares out.49.0M47.0M38.0M31.7M30.4M25.4M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−4.2%
Net margin
−4.5%
Return on equity
−7.4%
Return on assets
−2.8%
Return on capital (ROCE)
−3.5%
Liabilities / assets
62.7%
Debt / equity
1.68×
Book value / share
$6.42
Revenue growth (YoY)
54.7%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
0.54distress
Accruals / assets
−9.4%clean
Piotroski F-Score
6/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
63
/ 100
Profitability 0Growth 100Catalyst 67Earnings quality 100Financial strength 50

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 2 severe● 2 warning● 3 good
  • Altman Z″ in the distress zone
  • Filed a late-filing notice (Form NT) — missed an SEC deadline
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Revenue is growing year-over-year
  • Positive operating cash flow
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Risk flags

late SEC filings

A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.

FDA-approved drugs

openFDA · most recent
  • LIVMARLIApr 10, 2025
  • CTEXLIFeb 21, 2025
  • CHOLBAMMar 17, 2015

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Insider transactions

SEC Form 4 · most recent
0 acquisitions1 disposalsnet −9,108 shares · last 1
InsiderDateTypeSharesPrice
Peetz ChristopherOfficer — CHIEF EXECUTIVE OFFICERFeb 2, 2026Sell9,108$103.30

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 20268.2M4.8-2.6%
Apr 30, 20268.4M14.7+2.4%
Apr 15, 20268.2M12.5+2.0%
Mar 31, 20268.1M6.8+7.9%
Mar 13, 20267.5M9.1-2.1%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.